Anil Kumar Deshantri

Dr. Anil Kumar Deshantri

Sun Pharma Advanced Research Co. Ltd.
orcid

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 October 2018 in Journal of Controlled Release
Verified
Journal Article
Closed access
ADAnil Kumar Deshantri
Anil Kumar Deshantri
AMAida Varela Moreira
Aida Varela Moreira
VEVeronika Ecker
Veronika Ecker
SMSanjay N. Mandhane
Sanjay N. Mandhane
RSRaymond Schiffelers
Raymond Schiffelers
MFMarcel Fens
Marcel Fens

25 November 2019 in Cells
Verified
Journal Article
Open access
PDF file
NINazma Ilahibaks
Nazma Ilahibaks
ZLZhiyong Lei
Zhiyong Lei
EMEmma A. Mol
Emma A. Mol
ADAnil Kumar Deshantri
Anil Kumar Deshantri
LJLinglei Jiang
Linglei Jiang
JSJoost Sluijter
Joost Sluijter
Extracellular vesicles (EVs) are mediators of intercellular communication by transferring functional biomolecules from their originating cells to recipient cells. This intrinsic ability has gained EVs increased scientific interest in their use as a direct therapeutic in the field of regenerative medicine or as vehicles for drug delivery. EVs derived from stem cells or progenitor cells can act as paracrine mediators to promote repair and regeneration of damaged tissues. Despite substantial research efforts into EVs for various applications, their use remains limited by the lack of highly efficient and scalable production methods. Here, we present the biofabrication of cell-derived nanovesicles (NVs) as a scalable, efficient, and cost-effective production alternative to EVs. We demonstrate that NVs have a comparable size and morphology as EVs, but lack standard EV (surface) markers. Additionally, in vitro uptake experiments show that human fetal cardiac fibroblast, endothelial cells, and cardiomyocyte progenitor cells internalize NVs. We observed that cardiac progenitor cell-derived NVs and EVs are capable of activating mitogen-activated protein kinase 1/2 (MAPK1/2)-extracellular signal-regulated kinase, and that both NVs and EVs derived from A431 and HEK293 cells can functionally deliver Cre-recombinase mRNA or protein to other cells. These observations indicate that NVs may have similar functional properties as EVs. Therefore, NVs have the potential to be applied for therapeutic delivery and regenerative medicine purposes.

1 February 2019 in Journal of Controlled Release
Verified
Journal Article
Closed access
ADAnil Kumar Deshantri
Anil Kumar Deshantri
MFMarcel H. Fens
Marcel H. Fens
RRRuud W.J. Ruiter
Ruud W.J. Ruiter
JMJosbert M. Metselaar
Josbert M. Metselaar
GSGert Storm
Gert Storm
RSRaymond Schiffelers
Raymond Schiffelers

1 November 2018 in International Journal of Nanomedicine
Verified
Journal Article
Open access
PDF file
MBMaaike V.J. Braham
Maaike V.J. Braham
ADAnil Kumar Deshantri
Anil Kumar Deshantri
MMMonique C. Minnema
Monique C. Minnema
FÖF. Cumhur Öner
F. Cumhur Öner
RSRaymond M. Schiffelers
Raymond M. Schiffelers
JAJacqueline Alblas
Jacqueline Alblas
Purpose: Liposomal drug delivery can improve the therapeutic index of treatments for multiple myeloma. However, an appropriate 3D model for the in vitro evaluation of liposomal drug delivery is lacking. In this study, we applied a previously developed 3D bone marrow (BM) myeloma model to examine liposomal drug therapy. Material and methods: Liposomes of different sizes (~75–200 nm) were tested in a 3D BM myeloma model, based on multipotent mesenchymal stromal cells, endothelial progenitor cells, and myeloma cells cocultured in hydrogel. The behavior and efficacy of liposomal drug therapy was investigated, evaluating the feasibility of testing liposomal drug delivery in 3D in vitro. Intracellular uptake of untargeted and integrin α4β1 (very late antigen-4) targeted liposomes was compared in myeloma and supporting cells, as well as the effectivity of free and liposome-encapsulated chemotherapy (bortezomib, doxorubicin). Either cocultured myeloma cell lines or primary CD138+ myeloma cells received the treatments. Results: Liposomes (~75–110 nm) passively diffused throughout the heterogeneously porous (~80–850 nm) 3D hydrogel model after insertion. Cellular uptake of liposomes was observed and was increased by targeting very late antigen-4. Liposomal bortezomib and doxorubicin showed increased cytotoxic effects toward myeloma cells compared with the free drugs, using either a cell line or primary myeloma cells. Cytotoxicity toward supporting BM cells was reduced using liposomes. Conclusion: The 3D model allows the study of liposome-encapsulated molecules on multiple myeloma and supporting BM cells, looking at cellular targeting, and general efficacy of the given therapy. The advantages of liposomal drug delivery were demonstrated in a primary myeloma model, enabling the study of patient-to-patient responses to potential drugs and treatment regimes.

23 March 2019 in International Journal of Pharmaceutics: X
Verified
Journal Article
Open access
ADAnil Kumar Deshantri
Anil Kumar Deshantri
JMJosbert M. Metselaar
Josbert M. Metselaar
SZStavroula Zagkou
Stavroula Zagkou
GSGert Storm
Gert Storm
SMSanjay N. Mandhane
Sanjay N. Mandhane
RSRaymond Schiffelers
Raymond Schiffelers
Bortezomib is a proteasome inhibitor used for the treatment of multiple myeloma. The poor pharmacokinetic profile and off-target adverse effects provide a strong incentive to develop drug delivery systems for bortezomib. In the past, liposomal encapsulation has been proven to improve the therapeutic index of a variety of anti-neoplastic therapeutics. Here, we developed and characterized liposomal bortezomib formulations in order to find the most optimal loading conditions. Polyols were used to entrap bortezomib inside the liposomes as boronate ester via a remote loading strategy. Effect of various polyols, incubation duration, temperature, and total lipid concentration on loading efficiency was examined. Moreover, the effect of drug/lipid ratio on the release kinetics was studied. Loading efficiency was maximal when using meglumine plus mannitol as entrapping agents. Loading at room temperature was better than at 60 °C and loading efficiency was increased with increasing total lipid concentrations. There was a positive correlation between drug/lipid ratio and released amount of bortezomib. In vitro release kinetics in HBS and human plasma showed time dependent release. In HBS, at 4 °C, only 20% of the drug was released in three weeks, whereas at 37 °C 85% of the drug was released in 24 h. In human plasma, 5% of the drug retained after 24 h indicating faster release. Taken together, the most favorable liposomal formulation of bortezomib should be further exploited to study in vitro and in vivo efficacy performance.

1 December 2016 in Journal of Controlled Release
Verified
Journal Article
Closed access
ADAnil Kumar Deshantri
Anil Kumar Deshantri
Sander A.A. KooijmansSander A.A. Kooijmans
Sander A.A. Kooijmans
SKSylvia A. Kuijpers
Sylvia A. Kuijpers
MCMaria Coimbra
Maria Coimbra
AHAstrid Hoeppener
Astrid Hoeppener
RSRaymond Schiffelers
Raymond Schiffelers